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Advanced Heart Failure Therapeutics*
Joseph G. Rogers, MD, Christopher M. O’Connor, MDT he past decade has witnessed a rapid evolu-tion in the tools available to treat patientswith severe left ventricular systolic dysfunc-
tion. Gone are the days of managing advanced
heart failure with medical therapy alone. Patients
with heart failure who present for tertiary and quater-
nary cardiovascular care are often those who have
received evidence-based medical and electrical thera-
pies but have residual hemodynamic compromise.
The intra-aortic balloon pump (IABP), historically
used for its relative simplicity, has not withstood the
vicissitudes of rigorous clinical trials. The modest he-
modynamic support IABP provides has not been asso-
ciated with survival improvements in either acute
myocardial infarction (AMI) or cardiogenic shock (1,2).
As a result, both percutaneous and temporary
surgically implanted mechanical circulatory support
(MCS) devices are increasingly being used as adju-
vant support in high-risk revascularization and ven-
tricular tachycardia ablation procedures and to treat
cardiogenic shock. These devices have shown supe-
rior hemodynamic improvements relative to IABP,
reasonable safety proﬁles, and similarity to predicate
devices. However, a disconnect remains between the
hemodynamic beneﬁts of commonly used percuta-
neous devices and demonstrable outcome improve-
ment in clinical trials (3).SEE PAGE 1407In this issue of the Journal, Stretch et al. (4)
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devices from the National Inpatient Sample, a payer
registry consisting of approximately 20% of all U.S.
hospitalizations. The authors used billing codes to
identify patients treated with either a percutaneously
placed or surgically implanted temporary MCS device
and stratiﬁed patients by era of hospitalization
(2004 to 2007 and 2008 to 2011) to examine utiliza-
tion and outcome trends.
Although it can be difﬁcult to characterize patient
populations selected from administrative datasets,
important clues in this study highlight the dichoto-
mous use of short-term MCS devices in the United
States. One-half of patients in both eras were coded
as having cardiogenic shock, and 30% to 40% had a
primary diagnosis of AMI. Further, a sizable propor-
tion received an IABP, mechanical ventilation, or
cardiopulmonary resuscitation while hospitalized.
Conversely, 25% of the patients were electively
admitted to the hospital, suggesting that these de-
vices were placed in the context of an elective,
invasive cardiac procedure.
The authors demonstrated a dramatic increase
(>1,500%) in the use of percutaneous short-term MCS
devices from 2007 to 2011, whereas changes in the use
of IABP and surgically implanted short-term MCS
devices were less marked. This growth in the use of
short-term support devices was associated with
mortality reductions in the overall cohort and in the
subset of patients with cardiogenic shock, as well as
with a decrease in length of hospital stay and cost.
Several limitations of this analysis deserve com-
ment. First, the underlying cause for hospitalization
in nearly 25% of patients in this series is not classi-
ﬁed. As a result, it is difﬁcult to interpret the role
of temporary mechanically assisted circulation in
distinct patient subsets. Second, the impact of
device therapy on mortality reduction was not uni-
form. When stratiﬁed by primary diagnosis, no in-
dividual cohort demonstrated statistically signiﬁcant
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1417mortality reductions, and patients with antecedent
heart failure and valvular heart disease experienced
an increase in mortality suggesting that cardiovas-
cular specialists may be attempting to treat diseases
that heretofore were not approached. Going forward,
care must be taken to avoid use of temporary MCS
devices as a crutch to thoughtful risk stratiﬁcation
and decision making. Third, database analyses as such
often do not correct for important patient-speciﬁc
covariates such as severity and duration of shock,
degree of hemodynamic derangement, right ventric-
ular function, renal failure, and other biomarker
abnormalities.
Finally, in an era of emphasis on cost containment
in medicine, cost effectiveness must be considered
in our collective decisions to use various therapies.
Although the cost of hospital stays that included im-
plantation of a temporary MCS device was relatively
high ($116,858), the authors demonstrate a 22%
reduction in hospital costs during the observation
period. Similar improvements have been demon-
strated in the costs associated with durable MCS de-
vices (5). The reader is provided a myopic view of the
overall cost, opportunities, and impact of this support
strategy by examining hospital cost in isolation. For
example, the discharge-to-home rate increased 50%
with concomitant reductions in the use of nonhos-
pital inpatient days. The ﬁnancial impact of this
change must be included in the calculation of overall
cost effectiveness. Opportunities such as more rapid
implementation of MCS in appropriate patients may
reduce delays and avoid ineffective treatments asso-
ciated with morbidity and prolonged hospital stay.
Further, a proportion of these patients will require
therapeutic escalation to durable MCS devices or
transplant, a cost not considered in this analysis.A subtle undertone in this paper is worthy of
recognition. Increasingly, patients with advanced
heart disease are surrounded by integrated teams of
cardiologists and surgeons with focused expertise
and multimodality therapies that target the clinical
needs of this complex population. Considerable gains
have been made in improving processes of care for
patients with AMI by using a systems engineering and
team-based approaches. Similarly, combining revas-
cularization, antitachycardia treatments, and hemo-
dynamic support with contemporary medical therapy
has favorably altered the natural history of advanced
heart failure.
The cycle of innovation in patient care requires
novel insights from astute clinicians, diagnostic and
therapeutic advances, thoughtful review of out-
comes, and reﬁnement of the approach. The current
paper depicts this model, but many questions
remain. Who is the right patient for short-term me-
chanically assisted circulation, and when should
the device be implanted? Should other therapies
fail ﬁrst, what criteria should the practitioner use in
the decision to insert a temporary device? How long
should the device be utilized, and what are the
weaning criteria? Although important insights may
be gained from registries and observational studies,
these questions will best be answered in the context
of randomized controlled clinical trials.
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